Fast Novor Inc., the world’s chief in mass spectrometry (MS)-based antibody protein sequencing, introduced at present that its REpAb® antibody discovery platform was used to efficiently sequence a fancy combination of useful antibodies immediately from the serum of a human affected person after receiving a COVID-19 vaccine.
Picture Credit score: Fast Novor Inc.
This demonstrates a big breakthrough in antibody discovery expertise that bypasses the necessity to work with animal fashions, DNA, and cells. Sequencing useful antibody molecules produced and chosen by the human immune system in response to a menace may imply a way more direct path to discovering secure and efficient therapies”.
Xiaobing Han, Principal Scientist for Antibody Discovery, Fast Novor
The antigen itself was used to extract a polyclonal combination of related antibodies from the blood.
Sequencing evaluation of the polyclonal inhabitants resulted within the discovery of 12 distinctive monoclonal antibodies with a spread of binding affinities towards the antigen – from mid-picomolar to low nanomolar.”
Thierry Le Bihan, Principal Scientist for pAb sequencing, Fast Novor
Seven of the antibodies that demonstrated stronger affinity additionally demonstrated neutralization capabilities in vitro in opposition to a pseudovirus. From a minute human serum pattern quantity, REpAb® supplied the protein sequences mandatory for the technology and replica of functionally related antibodies – a feat that has but to be achieved in different research.
Combining Fast Novor’s REpAb® expertise with recombinant expression and cell-based assays supplied a sturdy workflow to decode the antibody inhabitants of a COVID-19-vaccinated particular person. The binding kinetics of those anti-SARS-CoV-2 antibodies had been characterised with floor plasmon resonance (SPR) kinetic evaluation. Epitope mapping will observe utilizing hydrogen-deuterium change mass spectrometry (HDX-MS). This workflow can doubtlessly present the knowledge wanted for future therapeutic antibody improvements.
The REpAb® expertise is well-positioned to suit into any therapeutic antibody discovery pipeline.”
Iain Rogers, VP Gross sales and Advertising, Fast Novor
With 40+ polyclonal antibody sequencing campaigns underneath their belt, the workforce at Fast Novor is actively working with pharmaceutical corporations and biotechnology companions to combine REpAb® into essential workflows for the invention of extremely potent and developable antibodies.
